Skip to main content
. Author manuscript; available in PMC: 2026 Jan 5.
Published in final edited form as: AAPS PharmSciTech. 2025 May 16;26(5):135. doi: 10.1208/s12249-025-03131-6

Figure 6:

Figure 6:

A: IVA plasma concentration vs time profile following the IV administration of free IVA to mice at a dose of 5 mg/kg (n=3, data points are means ± SD). B: Predicted and observed IVA plasma concentration vs time profile following the oral administration of either IVA/HP-β-CD (1:2) complexes or Kalydeco tablets at a dose of 25 mg/kg (n=1–3, data points are means ± SD).